(Q34478304)

2 August 2017

1 reference

title

Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments (English)

1 reference

2 August 2017

1 reference

1 reference

Dillman RO

1

1 reference

2 August 2017

publication date

1 January 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

19

1 reference

2 August 2017

issue

8

1 reference

2 August 2017

page(s)

833-841

1 reference

Monoclonal antibodies for treating cancer

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Antibodies as cytotoxic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Anti-idiotype immunization of cancer patients: modulation of the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Indium-111 monoclonal antibody B72.3 scintigraphy in colorectal cancer. Correlation with computed tomography, surgery, histopathology, immunohistology, and human immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Radioimmunotherapy: recent results and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Human anti-mouse antibody response in cancer patients following single low-dose injections of radiolabeled murine monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

A phase II trial of murine monoclonal antibody 17-1A and interferon-gamma: clinical and immunological data

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100107745

21 January 2018

Identifiers

DOI

10.1081/CNV-100107745

1 reference

2 August 2017

1 reference